272 related articles for article (PubMed ID: 25085841)
1. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.
Vallon V; Docherty NG
Exp Physiol; 2014 Sep; 99(9):1140-5. PubMed ID: 25085841
[TBL] [Abstract][Full Text] [Related]
2. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Rieg T; Gerasimova M; Murray F; Masuda T; Tang T; Rose M; Drucker DJ; Vallon V
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F963-71. PubMed ID: 22832924
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
[TBL] [Abstract][Full Text] [Related]
4. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
[TBL] [Abstract][Full Text] [Related]
5. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.
Schlatter P; Beglinger C; Drewe J; Gutmann H
Regul Pept; 2007 Jun; 141(1-3):120-8. PubMed ID: 17276524
[TBL] [Abstract][Full Text] [Related]
8. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
10. Abelmoschus esculentus subfractions improved nephropathy with regulating dipeptidyl peptidase-4 and type 1 glucagon-like peptide receptor in type 2 diabetic rats.
Peng CH; Lin HC; Lin CL; Wang CJ; Huang CN
J Food Drug Anal; 2019 Jan; 27(1):135-144. PubMed ID: 30648566
[TBL] [Abstract][Full Text] [Related]
11. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
Katagiri D; Hamasaki Y; Doi K; Okamoto K; Negishi K; Nangaku M; Noiri E
J Am Soc Nephrol; 2013 Dec; 24(12):2034-43. PubMed ID: 24092928
[TBL] [Abstract][Full Text] [Related]
12. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation.
Hviid AVR; Sørensen CM
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F443-F454. PubMed ID: 31841385
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
[TBL] [Abstract][Full Text] [Related]
15. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
16. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
[TBL] [Abstract][Full Text] [Related]
17. Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.
Moroi M; Kubota T
J Cardiovasc Pharmacol; 2015 Aug; 66(2):159-64. PubMed ID: 25853991
[TBL] [Abstract][Full Text] [Related]
18. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
